Zentalis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZNTL Nasdaq 2836 zentalis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zentalis Pharmaceuticals, Inc.

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Apr 12th, 2026 8:11 pm
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Apr 9th, 2026 6:00 am
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 1st, 2026 3:00 pm
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - Mar 26th, 2026 2:05 pm
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Mar 17th, 2026 2:30 pm
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - Feb 18th, 2026 6:00 am
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon - Feb 16th, 2026 3:09 am
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference - Feb 3rd, 2026 2:05 pm
Mitsui Sumitomo Continues to Build WR Berkley Stake - Jan 13th, 2026 6:45 am
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Jan 11th, 2026 3:08 pm
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Jan 8th, 2026 5:27 am
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - Jan 6th, 2026 6:00 am
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Dec 3rd, 2025 6:01 am
Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress - Nov 10th, 2025 2:05 pm
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 13th, 2025 2:05 pm
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock - Oct 6th, 2025 9:39 am
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary - Aug 26th, 2025 2:05 pm
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress - Aug 6th, 2025 2:05 pm
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company - Jul 23rd, 2025 10:34 am
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jul 1st, 2025 3:00 pm